Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Actelion says it performed well in 2008

Actelion says it performed well in 2008

19th February 2009

Actelion performed well in all important areas over the last 12 months, it has been claimed.

Managing director and chief executive officer of the firm Jean-Paul Clozel made this comment after the company released its full-year financial results for 2008.

The business achieved total net revenues of CHF 1,473.5 million (878,572.5 million pounds), compared to CHF 1,317.4 million the previous year.

It managed to lower its overall costs with operating expenses of CHF 1,102.2 million ? a saving of CHF 72.6 million.

Mr Clozel stated the firm’s product line continues to increase – despite increasing competition – and it currently has ten compounds being tested on humans.

“I expect product sales to grow and I expect more compounds to enter into man this year,” he asserted, adding the strengthening of the company’s global infrastructure and recruitment of top-class talent would help achieve this goal.

The year ahead has the potential for Actelion to transform, Mr Clozel concluded.

Work the company focused on in 2008 included the CRTH2 receptor antagonist, which could be potentially used against asthma and other allergies.

Actelion was founded in 1997.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.